Evaluate the safety (number of subjects with adverse events) of LIM-0705 administered to adult males and females with impaired glucose tolerance or abnormal HOMA-IR

Examine the pharmacokinetics (PK) of LIM-0705 as measured by area under the curve (AUC).

Explore the pharmacodynamics (PD) of LIM-0705 in obese adult males and females with impaired glucose tolerance or abnormal HOMA-IR as measured by change in response to hyperinsulinemic clamp, mixed-meal tolerance test (MMTT) between Days -2 and 27

(and 2 more...)

50

All

18 Years to 75 Years (Adult, Senior)

NCT01364155

LIM-0705-CL-2001

May 2011

August 2011

August 2011

June 2, 2011

June 2, 2011

Profil Institute of Clinical Research, Inc.Chula Vista, California, United States